Skip to main content

Table 3 Meta-analysis of the HIF-1α G1790A polymorphism and cancer risk

From: Association between HIF-1α C1772T/G1790A polymorphisms and cancer susceptibility: an updated systematic review and meta-analysis based on 40 case-control studies

Variables

  

AA vs.GG

GA vs. GG

AA + AG vs.GG

AA vs.GA + GG

A vs.G

Study

Case/control

I 2

Phet

OR (95% CI)

Case/control

I 2

Phet

OR (95% CI)

Case/control

I 2

Phet

OR (95% CI)

Case/control

I 2

Phet

OR (95% CI)

Case/control

I 2

Phet

OR (95% CI)

Overall

30

6538/9948

57

0.01

5.11 (2.08-12.56)*

7005/10442

77

<0.001

1.45 (1.05-1.99)*

7117/10442

83

<0.001

1.63 (1.16-2.30)*

7117/10442

58

0.01

4.41 (1.80-10.84)*

14234/20884

86

<0.001

1.77 (1.23-2.25)*

Overall in HWE

29

6449/9699

61

0.003

5.14 (1.67-15.86)*

6873/10138

69

<0.001

1.35 (1.01-1.81)*

6971/10154

79

<0.001

1.53 (1.10-2.12)*

6971/10154

60

0.004

4.80 (1.58-14.55)*

13942/20308

85

<0.001

1.70 (1.17-2.46)*

Cancer type

Breast

4

623/501

0

0.34

1.44 (0.38-5.44)

692/550

53

0.12

1.03 (0.70-1.52)

698/553

60

0.08

1.05 (0.72-1.53)

698/553

0

0.36

1.41 (0.37-5.40)

1396/1466

65

0.56

1.07 (0.76-1.52)

Cervical

3

708/819

0

0.99

0.35 (0.04-3.39)

740/871

57

0.13

0.62 (0.40-0.98)

740/837

51

0.15

0.60 (0.38-0.94)

740/837

0

0.99

0.36 (0.04-3.450

1480/1746

42

0.19

0.59 (0.38-0.91)

Oral

4

517/633

75

0.02

72.11 (2.08-2502.44)*

542/670

70

0.02

3.17 (1.26-7.92)*

583/670

92

<0.001

7.92 (1.58-39.64)*

583/670

75

0.02

58.05 (1.70-1985.77)*

1166/1340

96

0.01

9.66 (1.31-71.15)*

Prostate

3

1866/2230

-

-

-

1927/2280

1

0.37

1.42 (0.97-2.07)

1928/2280

7

0.34

1.44 (0.98-2.10)

1928/2280

-

-

-

3856/4560

10

0.33

1.45 (0.99-2.11)

Renal

4

1016/1267

0

0.95

5.10 (2.21-11.73)

1123/1354

92

<0.001

1.51 (0.45-5.05)*

1139/1364

92

<0.001

1.58 (0.49-5.04)*

1139/1364

0

0.76

3.09 (1.38-6.92)

2278/2728

89

<0.001

1.53 (0.60-3.92)*

Renal in HWE

3

937/1018

-

-

-

991/1076

0

0.42

1.00 (0.69-1.47)

993/1076

0

0.6

1.04 (0.71-1.52)

993/1076

-

-

-

1986/2152

0

0.78

1.07 (0.74-1.55)

Lung

3

405/481

0

0.87

5.42 (2.74-10.70)

466/555

0

0.57

1.72 (1.22-2.41)

509/566

0

0.46

2.14 (1.56-2.94)

509/566

0

0.79

4.52 (2.31-8.83)

1018/1132

0

0.48

2.27 (1.74-2.95)

Colorectal

2

545/2327

-

-

-

554/2336

-

-

-

554/2336

0

0.45

0.97 (0.57-1.63)

554/2336

-

-

-

1108/4672

-

-

-

Pancreatic

2

255/391

-

-

-

319/423

82

0.02

1.61 (0.24-10.76)*

322/423

63

0.1

3.14 (1.99-4.97)

322/423

-

-

-

644/846

0

0.42

3.08 (1.98-4.78)

Other

7

593/1377

-

-

-

642/1377

74

<0.001

1.53 (0.65-3.59)*

644/1377

72

<0.001

1.57 (0.70-3.53)*

644/1377

-

-

-

1288/2754

69

0.01

1.57 (0.75-3.30)*

Ethnicity

Asian

15

3607/4263

13

0.33

3.50 (2.05-5.98)

4010/4614

74

<0.001

1.44 (1.04-1.99)*

4063/4630

76

<0.001

1.49 (1.07-2.08)*

4063/4630

0

0.45

3.12 (1.83-5.32)

8126/9260

77

<0.001

1.49 (1.08-2.05)*

Caucasian

13

1829/4357

0

0.69

6.63 (3.11-14.12)

1926/4450

81

<0.001

1.36 (0.58-3.19)*

1948/4460

82

<0.001

1.45 (0.69-3.04)*

1948/4460

0

0.49

4.21 (2.04-8.71)

3896/8920

75

<0.001

1.65 (0.84-3.24)*

Caucasian in HWE

12

1750/4108

0

0.74

12.40 (2.19-70.22)

1794/4172

68

0.01

1.10 (0.48-2.49)*

1802/4172

67

0.01

1.22 (0.62-2.37)*

1802/4172

0

0.79

11.37 (2.02-63.93)

3604/8344

68

0.01

1.65 (1.17-2.32)*

Source of control

HB

13

3197/3945

45

0.12

1.54 (0.35-6.70)

3510/4234

77

<0.001

1.37 (0.92-2.05)*

3554/4248

79

<0.001

1.40 (0.93-2.11)*

3554/4248

35

0.19

3.13 (1.74-5.62)

7108/8496

79

<0.001

1.38 (0.93-2.05)*

PB

17

3133/5705

66

0.01

11.55 (6.62-20.12)*

3295/5882

78

<0.001

1.51 (0.88-2.58)*

3563/6194

85

<0.001

1.90 (1.06-3.39)*

3563/6194

69

0.002

10.27 (2.42-43.63)*

6726/11788

89

<0.001

2.25 (1.18-4.29)*

PB in HWE

16

3054/5456

67

0.006

15.51 (2.53-94.94)*

3163/5604

60

0.01

1.34 (0.85-2.11)*

3417/5906

81

<0.001

1.71 (0.97-3.03)*

3417/5906

66

0.007

14.20 (2.38-84.61)*

6434/11212

89

<0.001

2.33 (1.91-2.84)*

  1. HWE: Hardy-Weinberg Equilibrium; PB: population based; HB: hospital based; Phet: P value for heterogeneity. *Random-effects model was used when P value for heterogeneity test <0.05; otherwise, fixed-effects model was used.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us